RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:99967

Myxoid/round cell liposarcoma

high confidenceSubtype of disorder

Also known as: MRCLS

Publications

718

89.9th percentile

Trials

14

Interventional, condition-specific

Researchers

1,264

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Myxoid/round cell liposarcoma (MRCLS) is a type of liposarcoma (LS) mostly located in the limbs, with a variable behavior depending on the histological subtype. Both myxoid and round cell are distinct histological subtypes of LS.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

myxoid/round-cell liposarcoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    718 matched papers (481 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    14 matched on ClinicalTrials.gov (2 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

718

718 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

718 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

481 in the last 10 years · high confidence · 89.9th percentile (publications denominator)

Phrase hits: 718 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,264

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Pollack SM14 papers · 2026

    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

    Papers in Europe PMC
  2. 02
    Jones RL10 papers · 2025

    Sarcoma Unit, Royal Marsden Hospital NHS Trust and Institute of Cancer Research, London SW3 6JJ, UK.

    Papers in Europe PMC
  3. 03
    Wang X8 papers · 2026

    Department of Gynecologic Oncology, Gynecology and Obstetrics Centre, The First Hospital of Jilin University, Changchun, China.

    Papers in Europe PMC
  4. 04
    Somaiah N7 papers · 2026

    Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0450, Houston, TX 77030, USA.

    Papers in Europe PMC
  5. 05
    Wang W7 papers · 2026

    Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.

    Papers in Europe PMC
  6. 06
    Wu G6 papers · 2022

    Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.

    Papers in Europe PMC
  7. 07
    Blay JY5 papers · 2026

    Department of Medical Oncology, Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.

    Papers in Europe PMC
  8. 08
    Cranmer LD5 papers · 2024

    Department of Medical Oncology, University of Washington, Seattle, WA 98195, USA.

    Papers in Europe PMC
  9. 09
    Druta M5 papers · 2025

    Medical Oncology, Moffitt Cancer Center, Tampa, FL, United States.

    Papers in Europe PMC
  10. 10
    Wu T5 papers · 2022

    Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

14

interventional trials for this specific condition

14 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 120 trials are registered for liposarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

14 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 93.1th percentile).

high confidence · 93.1th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

14 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: liposarcoma

120

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Myxoid/round cell liposarcoma" OR "MRCLS" OR "myxoid/round-cell liposarcoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Myxoid/round cell liposarcoma" OR "MRCLS" OR "myxoid/round-cell liposarcoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 14 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"liposarcoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T06:48:13.460Z